Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879290 | 0.92 | LMNA (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL11207707 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL9193203 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL22856504 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL23806605 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL23695755 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL21106835 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL22861967 | 0.90 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL277921 | 0.85 | LMNA (0.45) | LMNACA2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2478778 | 0.85 | HRH4 (0.42) | HRH4HRH3ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20160304875-A1 | METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES | RXI PHARMACEUTICALS CORPORATION (US) | 2016-10-20 | — | — | US | disclosed |
| US-9340786-B2 | RNA interference in dermal and fibrotic indications | RXI PHARMACEUTICALS CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160130578-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | PHIO PHARMACEUTICALS CORP. | 2016-05-12 | — | — | US | disclosed |
| US-20160115482-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. | 2016-04-28 | — | — | US | disclosed |
| US-9080171-B2 | Reduced size self-delivering RNAi compounds | RXi Parmaceuticals Corporation (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140113950-A1 | INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130131141-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | PHIO PHARMACEUTICALS CORP. | 2013-05-23 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
| CN-1084739-C | Process for producing 2-hydroxybenzamide derivatives | ZERIA PHARMACEUTICAL CO.,LTD. (JP) | 2002-05-15 | — | — | CN | disclosed |
| CN-1261357-A | Process for preparing 2-hydroxybenzamide derivatives | ZERIA PHARM CO LTD (JP) | 2000-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304875-A1 | METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES | FN1, RXFP1, MMP1 | LMNA 1400/4885HRH4 2051/4885HRH3 1438/4885 |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | LMNA 1304/4885HRH4 503/4885HRH3 832/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | LMNA 4438/4885HRH4 3502/4885HRH3 4371/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20160115482-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | LMNA 1015/4885HRH4 771/4885HRH3 623/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.